Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma
- Resource Type
- Authors
- Dian, Zhou; Ying, Wang; Hai, Cheng; Lili, Zhu; Wei, Chen; Hujun, Li; Xiaotian, Zhang; Jieyun, Xia; Yuekun, Qi; Sha, Ma; Feng, Zhu; Zhiling, Yan; Kunming, Qi; Wei, Sang; Haiying, Sun; Depeng, Li; Jiang, Cao; Zhenyu, Li; Kailin, Xu
- Source
- Journal of Infection and Chemotherapy. 29:179-185
- Subject
- Microbiology (medical)
Infectious Diseases
Pharmacology (medical)
- Language
- ISSN
- 1341-321X
Chimeric antigen receptor (CAR) T-cell therapy is a new and effective method in relapsed or refractory (R/R) multiple myeloma (MM). This study was aimed to explore the risk factors of infection events.We retrospectively analyzed 68 patients with R/R MM who received CAR T-cell therapy at the Affiliated Hospital of Xuzhou Medical University from June 2017 to June 2021.35 patients received anti-CD19 combined with anti-BCMA CAR T-cell therapy and 33 patients received anti-BCMA CAR T-cell therapy alone.Infection events in patients who received ≥4 prior lines of treatment or with grade 3-5 cytokines released syndrome (CRS) mainly occurred within 4 months after CAR T-cell infusion(CTI). The duration of infection-free survival was positively correlated with progression-free survival of patients with R/R MM (RInfections after CTI were closely associated with more lines of prior treatment, longer duration of ANC500 cells/mm